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Abstract: Clinical applications of glucocorticoids (GC) in Oncology are dependent on their pro-apoptotic action to 
treat lymphoproliferative cancers, and to alleviate side effects induced by chemotherapy and/or radiotherapy. How-
ever, the mechanism(s) by which GC may also promote tumor progression remains unclear. GC receptor (GR) knock-
down decreases the antioxidant protection of highly metastatic B16-F10 melanoma cells. We hypothesize that 
a GR antagonist (RU486, mifepristone) could increase the efficacy of BRAF-related therapy in BRAFV600E-mutated 
metastatic melanoma. In vivo formed spontaneous skin tumors were reinoculated into nude mice to expand the 
metastases of different human BRAFV600E melanoma cells. The GR content of melanoma cell lines was measured 
by [3H]-labeled ligand binding assay. Nuclear Nrf2 and its transcription activity was investigated by RT-PCR, western 
blotting, and by measuring Nrf2- and redox state-related enzyme activities and metabolites. GR knockdown was 
achieved using lentivirus, and GR overexpression by transfection with the NR3C1 plasmid. shRNA-induced selective 
Bcl-xL, Mcl-1, AKT1 or NF-κB/p65 depletion was used to test the efficacy of vemurafenib (VMF) and RU486 against 
BRAFV600E-mutated metastatic melanoma. During early progression of skin melanoma metastases, RU486 and VMF 
induced a drastic metastases regression. However, treatment at an advanced stage of growth demonstrated the de-
velopment of resistance to RU486 and VMF. This resistance was mechanistically linked to overexpression of specific 
proteins of the Bcl-2 family (Bcl-xL and Mcl-1 in our experimental models). We found that melanoma resistance is 
decreased if AKT and NF-κB signaling pathways are blocked. Our results highlight mechanisms by which metastatic 
melanoma cells adapt to survive. 
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Introduction 
Metastatic melanoma is the least common skin 
cancer, but the most deadly because it spre- 
ads quickly and easily to other parts of the bo- 
dy [1]. Despite the availability of new targeted 
therapies, a significant unmet need in the treat-
ment of advanced melanoma remains [2].
GC are widely used in cancer therapy due to 
their pro-apoptotic properties in different tumor 
cells [3]. However GC may also induce a yet 
undefined resistant phenotype, thereby facili-
tating fast growth and metastases of different 
solid tumors [3, 4]. It has been observed that 
GC, at pathophysiological concentrations (non-
therapeutic), can induce anti-apoptotic signals 
that are associated with resistance to apopto-
sis of cells of epithelial origin and of most of 
malignant solid tumors submitted to cytotoxic 
therapy [5-7]. This apparent biological paradox 
could hypothetically reflect a difference in circu-
lating GC levels. Where pathophysiological lev-
els (e.g. those measured in the presence of a 
growing tumor) are lower than those reached if 
GC are administered (IV or IM) at pharmacologi-
cal doses.
We reported that GR knockdown diminishes 
the antioxidant protection of highly metastatic 
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B16-F10 melanoma cells and, thereby, causes 
a drastic decrease in their survival during inter-
action with vascular endothelial cells (which 
release reactive oxygen and nitrogen species) 
[8]. In vivo only 10% of the B16-F10 cells 
attached to the endothelium survived within 
the hepatic microcirculation (compared to 90% 
survival in the controls) [8]. 
The BRAFV600E mutation is the most commonly 
observed in patients, confers constitutive 
kinase activity, accounts for > 90% of BRAF 
mutations in melanoma, and is detected very 
early in melanoma development [9]. Interes- 
tingly, recent studies reveal that VMF/PLX40- 
32 (a selective inhibitor of mutant BRAFV600E) 
increases mitochondrial respiration and reac-
tive oxygen species (ROS) production in BR- 
AFV600E melanoma cell lines [10]. Thus we test-
ed the hypothesis that combination of a GR 
antagonist and VMF could induce regression of 
melanoma metastases.
Materials and methods
Culture of melanoma cells
Human A2058, COLO-679 and SK-Mel-28 mel-
anoma cells were from the ATCC (Manassas, 
VA). Cells were grown in DMEM (Invitrogen, San 
Diego, CA), pH 7.4, supplemented with 10% 
heat-inactivated FCS (Biochrom KG, Berlin, 
Germany), 100 units/mL penicillin and 100 μg/
mL streptomycin. Cells were plated (20,000 
cells/cm2) and cultured at 37°C in a humidified 
atmosphere with 5% CO2. Cells were harvested 
by incubation for 5 min with 0.05% (w/v) trypsin 
(Sigma Aldrich, St. Louis, MO) in PBS, pH 7.4, 
containing 0.3 mM EDTA, followed by the addi-
tion of 10% FCS to inactivate the trypsin. Cells 
were allowed to attach for 12 h before any 
treatment addition. Cell number and viability 
were determined using a BioRad (Hercules, CA) 
TC20 Automated Cell Counter. 
Animals and experimental metastases
Nude (nu/nu) mice (male, 9-10 weeks old, 
Charles River Laboratories, Wilmington, MA) 
were fed ad libitum on a standard diet (Letica, 
Rochester Hills, MI), and kept on a 12-h-light/ 
12-h-dark cycle with the room temperature at 
22°C. Procedures were in compliance with in- 
ternational laws and policies (EEC Directive 
86/609, OJ L 358. 1, December 12, 1987; and 
NIH Guide for the Care and Use of Laboratory 
Animals, NIH Publ. No. 85-23, 1985).
Skin metastases were reproduced by orthotop-
ic intradermic inoculation of metastatic A2058 
or COLO-679 melanoma cells. Metastatic mela-
noma cells were isolated (see below) from 
spontaneous skin metastases found in nu/nu 
mice s.c. xenografted with these tumors. The 
initial s.c. xenografted tumors were allowed to 
grow for 3 weeks and then were surgically 
removed. Spontaneous skin metastases were 
detected (in 10-15% of all mice and in different 
areas of skin to the initial location of the xeno-
grafts) 2-3 months later.
To generate orthotopic xenografts mice were 
inoculated intradermically (on the back) with 2 
× 106 metastatic melanoma cells per mouse. 
During the time frame of our experiments, the 
reinoculated metastatic cells grew as a single 
tumor. Tumor volume was measured using cali-
pers, and expressed in mm3 according to V = 
0.5a × b2 (a and b are the long and short diam-
eters, respectively). For histological analysis 
skin tumors were fixed in 4% formaldehyde in 
PBS (pH, 7.4) for 24 h at 4°C, paraffin embed-
ded, and stained with hematoxilin & eosin and 
safran. The sacrifice was performed by cervical 
dislocation.
RU486 and vemurafenib administration to 
tumor-bearing mice
Based on published human and murine phar-
macokinetics, dosage used to treat Cushing’s 
syndrome in humans (300-1200 mg of RU486, 
oral, once a day), and FDA’s recommendations 
for murine equivalent doses (www.fda.gov), we 
calculated a clinically relevant dose of 10 mg 
RU486/kg of mouse which was administered 
i.p., once a day, in 7-8 μL of dimethyl formamide 
per mouse. 
The recommended dose of VMF in cancer 
patients is 960 mg (oral, twice a day) [11], and 
following the same criteria used for RU486, we 
calculated a clinically relevant dose of 45 mg 
VMF/kg of mouse. VMF, formulated in the same 
high-bioavailability microprecipitated bulk pow-
der formulation used in patients, was suspend-
ed in an aqueous vehicle containing 2% Klucel 
LF (Hercules Inc., Wilmington, DE) and adjusted 
to pH 4 with dilute HCl. Vehicle control and VMF 
were given orally (once a day) using a sterile 
Glucocorticoid receptor antagonism in metastatic melanoma
2582 Am J Cancer Res 2019;9(12):2580-2598
1-mL syringe and 18-gauge gavage needle 
(200 μL per mouse) at the dose indicated 
above. 
Isolation of tumor cells from skin metastases 
using enzymatic digestion and a double Ficoll 
gradient
To maximize cell yield and viability we used col-
lagenase III (200 U/mL; Sigma-Aldrich), DNase 
I (200 U/mL; Sigma-Aldrich) and trypsin (5 mg/
mL; Invitrogen), and a non-enzymatic dissocia-
tion buffer (NEDB, Invitrogen). The mice were 
killed, and the tumors were removed into cold 
culture media. The tumors were minced into 
1-3 mm fragments, and then incubated with 
the dissociation solution (see above) × 30 min 
at 37°C. The tumor fragments were mixed up 
and down every 10 min using a 1000 μL micro-
pipette with a tip. After each incubation, the 
fragments were filtered through a 40 mm nylon 
mesh cell strainer (BD Biosciences, San Diego, 
CA). The released cells were centrifuged at 
1200 rpm × 2 min and stored in cold CO2-
independent medium with 30% FCS at 4°C. 
Fresh dissociation solution was added to the 
remaining tissue fragments for 30 min. The 
fragments were pushed through a sieve. The 
dissociated cells were layered onto a double 
Ficoll gradient (Histopaque; Sigma Aldrich; 
densities 1.077 and 1.119) and spun at 700 × 
g for 30 min at room temperature. Cells re- 
moved from both interfaces were pooled and 
washed two times in CO2-independent me- 
dium and stored at 4°C. 
Measurement of the GR content of melanoma 
cell lines by [3H]-labeled ligand binding assay
The GR content was measured by a whole-cell 
binding assay as previously described [12]. The 
melanoma cells were exposed to various con-
centrations of [3H]-dexamethasone (DXM) (GE 
Healthcare Life Sciences, Björkgatan, Uppsala, 
Sweden) in the presence or absence of unla-
beled DXM. Using the specific activity of 
[3H]-DXM, the GR number/cell was calculated, 
assuming that each receptor binds to one 
DXM molecule.
Enzyme assays
Isolated tumor cells were homogenized in 0.1 
M phosphate buffer (pH 7.2) at 4°C. γ-glu- 
tamylcysteine ligase (GCL), GSH synthase 
(GSS), glutathione peroxidase (GPX), glutathi-
one S transferase (GST), thioredoxin reductase 
(TXNRD), superoxide dismutase 1 and 2 (SOD1 
and SOD2), catalase (CAT), and NADPH oxida- 
se 1 (NOX 1) activities were measured follow- 
ing previously reported methodology [12]. Pro- 
tein concentration was determined with the 
Pierce BCA protein assay (Thermo Fisher Sci- 
entific, Waltham, MA).
Measurement of H2O2 and O2
.-
Quantitative measurement of H2O2 and flow 
cytometric determination of O2
.--generation 
were performed as previously described [12].
Glutathione, glutathione disulfide, thioredoxin, 
NADP+, and NADPH determination
GSH (glutathione, γ-L-glutamyl-L-cystenyl-gly- 
cine) and GSSG (glutathione disulfide) were 
determined by LC/MS as previously reported 
[8]. Thioredoxin (TXN) was quantitated using an 
assay kit from Cayman Chemical (Ann Arbor, 
MI). NADP+ and NADPH were quantitated using 
an assay kit from Sigma Aldrich.
Lipid peroxidation
For isoprostane determination, tumor samples 
were homogenized in 0.1 M phosphate buf- 
fer (pH 7.4)+1 mM EDTA+0.005% butylated 
hydroxytoluene. Isoprostanes were measured 
using the 8-isoprostane EIA kit (Cayman Che- 
mical) and following the manufacturer’s proto- 
col.
RT-PCR and detection of mRNA
Total RNA was isolated using the TRIzol kit 
from Invitrogen following the manufacturer’s 
instructions. cDNA was obtained using a ran-
dom hexamer primer and a MultiScribe Rever- 
se Transcriptase kit as recommended by the 
manufacturer (Taq-Man RT Reagents; Applied 
Biosystems, Foster City, CA). PCR master mix 
and AmpliTaq Gold DNA polymerase (Applied 
Biosystems) were added to the primers previ-
ously reported [12]. Real-time quantification of 
mRNA relative to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was performed as pre-
viously reported [12]. 
Western blots
Western blot analysis was performed as previ-
ously described [12]. Proteins were transferred 
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to a nitrocellulose membrane and subjected to 
western blotting with specific anti-human mo- 
noclonal antibodies (OriGene, Rockville, MD; 
and Santa Cruz Biotechnology, Dallas, TX). 
Blots were developed using horseradish pe- 
roxidase-conjugated secondary antibody and 
enhanced chemiluminescence (ECL system; 
GE Health Care Life Sciences). Protein bands 
were quantified using laser densitometry.
Nrf2 gene transfer and measurement
The Tet-Off Advanced Inducible Gene Expres- 
sion System (Clontech, Mountain View, CA) was 
used, as previously described [12], to insert 
the human Nrf2 [nuclear factor (erythroid-
derived 2)-like 2] gene and for transfection into 
melanoma cells. The NE-PER extraction kit 
from Thermo Fisher Scientific was used for nu- 
clear protein extraction according to the manu-
facturer’s instructions. 
Immunohistochemistry and cell death analysis
Mouse anti-human HMB45 monoclonal anti-
bodies (Abcam, Cambridge, UK) were used for 
immunohistochemical detection of human mel-
anoma cells; whereas monoclonal mouse anti-
human Ki-67 antibodies (Dako, SantCugat del 
Vallés, Spain) were used for immunohistochem-
ical detection of the tumor-growing fraction 
(see [12]). DNA strand breaks in apoptotic cells 
were assayed using a TUNEL labeling assay 
(Roche, Basel, Switzerland), fluorescence mi- 
croscopy and manufacturer’s methodology. 
Apoptotic and necrotic cell death were distin-
guished by using fluorescence microscopy as 
previously described [13]. 
Glucocorticoid receptor knockdown: lentivirus 
production, titering, and transduction of target 
cell lines
HEK-293T cells (ATCC) used for lentiviral pro-
duction were grown in DMEM containing 10% 
FBS, 4.5 g/l glucose, 50 U/ml penicillin, 50 
mg/ml streptomycin, 1 mM sodium pyruvate, 4 
mM L-glutamine, and 0.1 mM non-essential 
amino acids. The procedure followed metho- 
dology previously reported in detail [8]. Cells 
transfected with retroviral vector harboring the 
GFP gene were used as a negative control. 
Established clones were grown as described 
above in medium supplemented with 0.5 mg/
ml puromycin. Silencing was confirmed by 
immunoblotting. The anti-human GR monoclo-
nal antibodies were purchased from Santa Cruz 
Biotechnology.
GR overexpression and analysis
GR overexpression was induced by transfecting 
the melanoma cells with nuclear receptor sub-
family 3 group C member 1 [Homo sapiens 
nuclear receptor subfamily 3 group C member 
1 (NR3C1), transcript variant 1, mRNA]-encod-
ing DNA plasmids as previously described for 
human triple-negative breast cancer cells [14]. 
The coding sequence (CCDS4278.1) of the pre-
dominant glucocorticoid receptor gene NR3C1 
transcript variant 1 (NM_000176.2) was syn-
thesized with the restriction sites KpnI and 
XhoI on the 5’ and 3’ end, respectively (In- 
vivoGen, San Diego, CA), and cloned in frame 
into the pcDNA6/V5-His A vector (Life Tech- 
nologies, Alcobendas, Spain). The cells were 
transfected with the NR3C1 plasmid (0.4 µg) 
for 24 h using Lipofectamine 2000 transfecti- 
on reagent (Invitrogen). Following 30 h of culti-
vation, the cells had reached 90% confluency, 
and were rinsed once with HBSS before pro-
ceeding to total RNA extraction. The GR content 
was measured by a whole-cell binding assay as 
described above.
Measurement of corticosterone and dexa-
methasone 
Plasma levels of corticosterone (Kamiyama 
Biomedical Co., Seattle, WA) and DXM (Bioo 
Scientific, Austin, TX) were quantified by ELISA 
according to the suppliers’ instructions.
Evaluation of drug-induced in vivo toxicity
This included the following parameters: blood 
cell count and chemistry based on NIH stan-
dard methodology, and urinalysis based on the 
Combur test from Roche. Urine pH was directly 
measured using a pH meter and urine protein 
content with the Pierce BCA Protein Assay Kit. 
The glomerular filtration rate (GFR) was evalu-
ated following the single bolus FITC-inulin clear-
ance methodology described for mice by [15].
Isolation and incubation of hepatocytes and 
lymphocytes
Isolation procedures followed previously report-
ed methodology [16, 17]. Rates of glucose and 
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glutamine utilization were measured as previ-
ously described [18].
Culture of hepatocytes
Isolated hepatocytes were diluted with warm 
William’s complete medium to 2.5 × 105 cells/
mL, and plated in un-coated cultured flasks at 
a ratio of 5 × 105 cells/cm2. Cells were cultured 
at 37°C in a humidified atmosphere of 95% air 
and 5% CO2.
shRNA expression vectors
HEK-293T cells (ATCC) used for lentiviral pro-
duction were grown in DMEM containing 10% 
FBS, 4.5 g/L glucose, 50 U/mL penicillin, 50 
mg/mL streptomycin, 1 mM sodium pyruvate, 4 
mM L-glutamine, and 0.1 mM non-essential 
amino acids. The LENTI-Smart system from 
InvivoGen was used according to the manufac-
turer’s protocol [bcl-xL shRNA, mcl-1 shRNA, 
AKT1 shRNA, and NF-κB/p65 shRNA were 
designed from the Ensemble genome browser/
database (Ensembl, the Wellcome Trust Geno- 
me Campus, Cambridge, UK) to target the fol-
lowing blc-xl, mcl-1 gene, AKT1, NF-κB/p65 
sequences: bcl-xl, 5’-GGAGATGCAGGTATTGGT- 




3’]. Scrambled sequences were used as con-
trols. Cells transfected with lentiviral vectors 
not harboring any gene (InvivoGen) were used 
as negative controls. Lentiviral particles were 
collected 48 h after transfection. Cell/viral 
debris was removed from the collected super-
natants by centrifugation (2000 rpm × 65 min) 
and filtration using a 0.45 mm PVDF (low pro-
tein binding) filter. Lentiviral particles were 
concentrated by ultracentrifugation (70000 × g 
for 2 h at 4°C). The fibrosarcoma cell line 
HT1080 (ATCC) was used for titering lentiviral 
vectors using the GFP within the transfer con-
struct as a marker for microscopic analysis. 
Lentiviral vectors contain the viral capsid pro-
tein (p24), which is encoded by the gag gene. 
An ELISA was used to determine the amount of 
p24 in the supernatant. Forty-eight hours fol-
lowing viral transduction, the number of GFP-
positive colonies per well was counted by fluo-
rescence microscopy. Transducing units per 
milliliter was calculated as follows: (T × V)/N, 
where T is the titer of the lentiviral vector stock, 
V is the volume of lentiviral vectors (in mL), and 
N is the number of cells to be transduced. 
Melanoma cell variants were transduced and 
subsequently selected by puromycin treatment 
to produce melanoma bcl-xl, mcl-1, AKT1, or 
NF-κB/p65 shRNA cell variants. Clonal popula-
tions of each cell line were obtained by flow 
cytometric cell sorting. Cells transfected with 
retroviral vector harboring the GFP gene were 
used as a negative control. Established clones 
were grown as described above in medium 
supplemented with 0.5 mg/mL puromycin. Si- 
lencing was confirmed by immunoblotting. The 
anti-human Bcl-xl, Mcl-1, AKT1, and NF-κB/p65 
monoclonal antibodies were from Santa Cruz 
Biotechnology.
Nuclear factor-κB DNA binding
Nuclear factor-κB (NF-κB) p50/65 DNA binding 
activity in nuclear extracts was carried out to 
measure the degree of NF-κB activation. 
Nuclear extract was prepared using the NE- 
PER™ Nuclear and Cytoplasmic Extraction pro-
cedure of Thermo Fisher Scientific, and follow-
ing manufacturer’s instructions. An ELISA was 
done in line with the manufacturer’s protocol 
for a commercial kit (Chemiluminescent NF- 
κB p50/65 Transcription Factor Assay, Oxford 
Biomedical Research, Rochester Hills, MI). An- 
tibodies anti-cyclin D1 were used as negative 
controls.
Statistics
Data are presented as mean values ± SD for 
the number of different experiments. Statistical 
analyses were performed using Student’s 
t-test, and P < 0.05 was considered signi- 
ficant. 
Results
Effect of RU486 on the antioxidant defense 
system of in vivo growing BRAFV600E-mutated 
metastatic melanoma cells
Human melanoma cells express high-affinity 
GR [19]. We investigated if pharmacologically 
relevant doses of RU486 (mifepristone, a GR 
antagonist) [20] could decrease the antioxi- 
dant protection of human BRAFV600E melanoma 
cell lines. 
After the initial xenografted tumors were re- 
moved, in vivo formed spontaneous skin tumors 
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were intradermically reinoculated into mice to 
expand the experimental metastases (see 
under Experimental procedures). Three differ-
ent human BRAFV600E melanoma cells were 
used (A2058, COLO-679 and SK-Mel-28, see 
Table S1 (available on request from the corre-
sponding author) for their genetic background). 
However only A2058 and COLO-679 cells gen-
erated spontaneous metastases.
As shown in Table 1, administration of RU486 
(10 mg/kg IP, QD) to mice bearing metastatic 
BRAFV600E-mutated (iA2058 and iCOLO-679) 
melanoma cells caused in both tumors a 
decrease in different Nrf2- and redox state-
related enzyme activities and metabolites, i.e. 
GCL, GSS, GPX, GST, GSH, TXN, TXNRD, SOD1, 
CAT, and different NADPH supplying dehydro- 
genases; and a parallel increase in the genera-
tion of superoxide anion radicals (O2
.-). As com-
pared to the controls (untreated metastatic 
tumor-bearing mice) expression of practically 
all tested Nrf2-dependent enzymes, excepting 
NOX1, decreased in RU486-treated mice bear-
Table 1. Effect of RU486 on different Nrf-2- and redox state-related enzyme activities and metabo-
lites in metastatic BRAFV600E-mutated melanoma cells growing in vivo
iA2058 iCOLO-679
- RU486 - RU486
GSH and TXN
    GCL (mU/106 cells) 146 ± 31 79 ± 26# 192 ± 49 102 ± 36*
    GSS (mU/106 cells) 19.2 ± 4.5 11.4 ± 2.9* 25.6 ± 6.6 14.7 ± 3.4#
    GPX (mU/106 cells) 6.5 ± 1.2 3.7 ± 1.1# 5.4 ± 1.0 2.1 ± 0.5#
    GSR (mU/106 cells) 11.7 ± 2.4 8.7 ± 1.5 13.8 ± 1.9 8.0 ± 2.3*
    GST (mU/106 cells) 12.3 ± 2.0 5.0 ± 1.3# 10.4 ± 1.9 4.3 ± 1.4#
    GGT (mU/106 cells) 26.1 ± 5.0 24.7 ± 5.5 33.9 ± 7.4 30.6 ± 6.0
    GSH (nmol/106 cells) 27.5 ± 4.1 13.4 ± 2.7# 44.8 ± 8.3 19.5 ± 3.7#
    GSSG (nmol/106 cells) 0.2 ± 0.1 0.3 ± 0.1 0.2 ± 0.05 0.3 ± 0.1
    TXN (μg/106 cells) 1.5 ± 0.4 0.9 ± 0.3* 1.9 ± 0.5 0.9 ± 0.2#
    TXNRD (U/106 cells) 1.7 ± 0.3 1.0 ± 0.2* 2.1 ± 0.6 0.9 ± 0.2#
ROS
    SOD1 (U/106 cells) 1.7 ± 0.3 0.8 ± 0.2# 1.9 ± 0.4 0.8 ± 0.15#
    SOD2 (U/106 cells) 0.2 ± 0.1 0.15 ± 0.05 0.3 ± 0.1 0.2 ± 0.1
    CAT (mU/106 cells) 3.1 ± 0.7 1.2 ± 0.2# 3.8 ± 0.5 1.3 ± 0.4#
    NOX (R.L.U./106 cells) 147 ± 36 157 ± 44 155 ± 26 133 ± 31
    H2O2 (nmol/10
6 cells x min) 1.4 ± 0.3 1.2 ± 0.2 2.0 ± 0.3 1.8 ± 0.2
    O2
.- (ΔFL1, a.u.) 1.9 ± 0.5 4.5 ± 0.9# 2.4 ± 0.5 5.9 ± 1.2#
NADPH supplying dehydrogenases
    G6PDH (mU/106 cells) 725 ± 102 466 ± 69# 857 ± 136 490 ± 77#
    ME (mU/106 cells) 89 ± 15 47 ± 10# 72 ± 17 38 ± 11#
    IDH (U/106 cells) 2.0 ± 0.3 1.2 ± 0.3* 1.7 ± 0.5 1.4 ± 0.2
Redox state
    NADPH (nmol/mg prot.) 0.16 ± 0.04 0.1 ± 0.005# 0.2 ± 0.06 0.12 ± 0.02*
    NADP+ (nmol/mg prot.) 0.01 ± 0.005 0.01 ± 0.005 0.01 ± 0.005 0.01 ± 0.002
    GSH/GSSG 138 ± 15 45 ± 11# 224 ± 36 66 ± 18#
    NADPH/NADP+ 16.2 ± 2.5 10.1 ± 1.6# 20.3 ± 3.7 12.3 ± 4.5*
Tumor-bearing mice were treated with vehicle (controls) or RU486 (10 mg/kg IP, QD, see under Materials and Methods). 
RU486 was administered for 3 weeks starting one week after intradermic inoculation of the cancer cells. All parameters were 
measured in melanoma cells isolated from tumors 28 days after inoculation. Data are mean values SD for six to seven differ-
ent tumors per parameter and experimental condition. *P < 0.05, #P < 0.01, comparing cells isolated from RU486-treated mice 
vs. controls. CAT, catalase; GCL, γ-glutamylcysteine ligase; GGT, γ-glutamyltranspeptidase; GSR, glutathione reductase; GSS, 
GSH synthase; NOX, NADPH oxidase; GPX, glutathione peroxidase; Nrf2, nuclear factor (erythroid-derived 2)-like 2; ROS, reac-
tive oxygen species; SOD, superoxide dismutase.
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ing iA2058 or iCOLO-679 melanoma cells 
(Figure 1A). RU486 treatment also associated 
with an increase of isoprostanes (a marker of 
oxidative stress) in the cancer cells (Figure S1, 
available on request from the corresponding 
author).
As shown in Figure 1B, and compared to con-
trol melanoma-bearing mice, these effects 
associated with a decrease in nuclear Nfr2 in 
metastatic melanoma cells from in vivo RU486-
treated mice. Moreover, melanoma cells engi-
neered to overexpress Nrf2 were able to grow 
in vivo as controls, despite treatment with 
RU486 (Figure 1C). As shown in Figure S2 
(available on request from the corresponding 
author), in melanoma cells engineered to over-
express Nrf2, expression of all Nrf2-dependent 
practically returned to control values (close to 
those found in control tumor-bearing mice 
treated with physiological saline) despite treat-
ment with RU486 (see also Figure 1). RU486 
Figure 1. Effect of RU486 on nuclear Nrf2 and its transcription activity in metastatic BRAFV600E-mutated melano-
ma-bearing mice. (A) Expression of different Nrf2-dependent genes in isolated iA2058 and iCOLO-679 cells from 
RU486-treated tumor-bearing mice (as in Table 1) was compared vs. control tumor-bearing mice treated with physi-
ological saline (*P < 0.05, **P < 0.01). All data, expressing fold change (quantitative RT-PCR), show mean values ± 
SD for five to six different experiments. (B) Effect of RU486 treatment on the nuclear accumulation of Nrf2 (western 
blots) in in vivo growing iA2058, iA2058/Tet-Nrf2, iCOLO-679, and iCOLO-679/Tet-Nrf2 cells (mean values ± SD for 
five different experiments (**P < 0.01, comparing RU486 treatment vs. controls). An empty vector (the regulatory 
plasmid pTett-Off without the Nrf2 gene sequence) was used as a control. Results obtained in cells transfected with 
this empty vector were not significantly different from those obtained in the control iA2058 and iCOLO-679 cells. (C) 
Effect of Nrf2 overexpression (see under Materials and Methods) on the tumor growth of control and RU486-treated 
iA2058- and iCOLO-679-bearing mice. Results obtained in these cells transfected with lentiviral vector not harbor-
ing any gene (negative control) were not different from control values. Data are mean values ± SD from five to six 
different experiments (*P < 0.05, **P < 0.01, comparing RU486 treatment vs. controls. For experiments (B) and (C) 
no significant differences were found when iA2058/Tet-Nrf2 cells or iCOLO679/Tet-Nrf2 ± RU486 treatment, were 
compared with control untreated cells.
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administration caused a decrease in melano-
ma cell proliferation (Ki-67 staining) and an 
increase in apoptotic cell death (TUNEL) (Figure 
2). The number of GR in iA2058 and iCOLO-679 
melanoma cells was of 87 ± 11 and 69 ± 7 × 
103 GR/cell (n = 6-7 different determinations in 
each case), respectively. These numbers of GR 
were similar in control A2058 and COLO-679 
cells (83 ± 9 × 103 and 63 ± 8 × 103 GR/cell, 
respectively, n = 6-7), and were not significantly 
affected by the in vivo treatment with RU486 
(90 ± 10 × 103 GR/iA2058 cell and 72 ± 11 × 
103 GR/COLO-679 cell, n = 7) or by Nrf2 gene 
transfer-induced Nrf2 overexpression (80 ± 11 
× 103 GR/iA2058 cell and 61 ± 7 × 103 GR/
COLO-679 cell, n = 6).
These results, indicating a clear link between 
Nrf2-dependent transcription activity and the 
GR antagonist-induced inhibition of metastatic 
melanoma growth, may be particularly relevant 
since Nrf2 can increase in e.g. lung carcinoma 
[21] or melanoma [22] cell proliferation and 
pharmacological resistance.
Combined GR antagonism and BRAF inhibi-
tion promotes regression of early melanoma 
metastases
Common oncogenes, such as KRAS, BRAF and 
MYC, increase the transcription and activity of 
Nrf2 causing an increase in tumor cell protec-
tion and, most notably, a decrease in ROS lev-
els [23]. The finding that BRAF stimulates tran-
scription of Nrf2 by elevating levels of JUN, 
which in turn binds to known start sites for tran-
scription of Nrf2, indicates that some of these 
effects are direct [23]. These evidences (in 
addition to its known role in regulating the MAP 
kinase/ERKs signaling pathway) prompted us 
to investigate if BRAF inhibition could potenti-
ate the antitumor effect elicited by the GR 
antagonist. As shown in Figure 3, combined 
treatment with RU486 and vemurafenib (VMF; 
which specifically interrupts the BRAF/MEK 
step in the BRAF/MEK/ERK pathway if the 
BRAF has the common V600E mutation) in- 
duced a complete inhibition of BRAFV600E-mu- 
tated metastatic melanoma growth under in 
vivo conditions. VMF-induced BRAF downregu-
lation was confirmed by western blot (see 
Figure 4). However early or late administration 
of VMF alone (7 or 14 days, respectively, after 
inoculation) did not decreased significantly the 
rate of metastatic melanoma growth as com-
pared to controls (Figure 3 displays the results 
obtained after early administration). Tumor gr- 
owth inhibition was observed if RU486 and 
VMF were administered simultaneously and 
starting 7 days after melanoma inoculation 
(Figure 3). If administration of VMF was delayed 
and started 14 days after melanoma inocula-
tion the inhibitory effect of the association 
practically disappeared (Figure 3). This differ-
ence depending on whether VMF administra-
tion is performed early or late suggests that 
during its in vivo growth, and despite the treat-
ment with RU486, metastatic melanoma spon-
Figure 2. Effect of RU486 on the rates of tumor cell proliferation and apoptotic death in vivo. For each experimental 
condition, a representative picture is shown: immunohistochemical detection of melanoma cells using HMB45 
monoclonal antibodies, cell proliferation detection using anti-Ki-67 monoclonal antibodies, and TUNEL staining 
showing melanoma cells with apoptotic nuclei. Proliferation and apoptotic indexes (expressed as % of Ki-67- and 
TUNEL-positive cells relative to controls, respectively) were calculated using ten 10 × 10-mm2 sections per tumor 
and randomly selecting four different areas per section. All data are mean values ± SD of seven to eight different 
animals or experiments (**P < 0.01, comparing RU486-treated mice vs. controls).
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Figure 3. Effect of RU486 and/or vemurafenib treatment on metastatic 
BRAFV600E-mutated melanoma growth. RU486 was administered for 3 
weeks (from day 7 to day 28, as in Table 1). VMF (45 mg/kg QD, see un-
der Materials and Methods) was administered for 3 weeks starting on day 
7 after intradermic inoculation [VMF (7)] of the cancer cells; or 2 weeks 
starting on day 14 after inoculation [VMF (14)]. All data are mean values ± 
SD of 9-10 different animals in all groups (*P < 0.05, comparing RU486- 
and/or VMF-treated mice vs. controls; #P < 0.05 comparing RU486+VMF-
treated vs. RU486-treated; +P < 0.05 comparing RU486+VMF-treated vs. 
VMF-treated).
Figure 4. Vemurafenib decreases BRAF levels in met-
astatic BRAFV600E-mutated melanoma tumors. VMF 
(45 mg/kg QD, see under Experimental procedures) 
was administered for 2 weeks starting on day 7 af-
ter intradermic inoculation. Protein levels (western 
blots) were measured in metastatic cells 21 days af-
ter inoculation (n = 4-5, **P < 0.01, comparing cells 
isolated from VMF-treated mice vs. controls).
taneously develops anti-VMF resistance mech-
anisms. In our models, resistance to VMF was 
associated with late administration of VMF. 
Based on our results, possible differences in 
BRAF signaling do not seem to explain why if 
administration of VMF was started 14 days 
after melanoma inoculation the inhibitory ef- 
fect of the association (RU486+VMF) practical-
ly disappeared.
It is a known fact that the anti-
tumorigenic effects elicited by 
VMF are short-lived and that 
the majority of patients pres-
ent tumor relapse in a short 
period after treatment [24]. 
The effects of RU486 are GR 
dependent 
RU-486 (used for medical ab- 
ortion) is a steroidal antipro-
gestogen, as well as an antiglu-
cocorticoid, and antiandrogen 
to a much lesser extent ([20] 
and refs. therein). It is obvious-
ly critical to elucidate if the 
anti-metastatic effects of RU- 
486 are totally or partially de- 
pendent on GR. As shown in 
Figure 5A and 5B GR knock-
down (see also Figure 5C and 
5D) or treatment with RU486 rendered similar 
results in both melanoma cell lines. However, 
metastatic growth was not significantly differ-
ent in control or melanoma cells overexpress-
ing the GR (Figure 5A-C). A fact probably indi-
cating that the number of GR present in control 
cells already ensure a full GR-dependent effect.
We investigated if administration of a specific 
GR agonist (such as DXM) protects melanoma 
from cells from VMF. As shown in Figure 6 plas-
ma levels of corticosterone (the main circulat-
ing glucocorticoid in mice [25]) and DXM, as 
well as metastatic tumor growth, were mea-
sured after the administration of DXM (the dose 
was selected taking into account that plasma 
levels should reflect pathophysiological condi-
tions in mice). DXM administration decreased 
corticosterone levels in the plasma of melano-
ma-bearing mice (Figure 6C). As shown in 
Figure 6A and 6B, the effect of VMF on meta-
static tumor growth was abolished by DXM. 
Anti-death adaptations related to the Bcl-2 
family of proteins in advanced BRAFV600E-
mutated melanoma metastases
Most mechanisms of acquired melanoma resis-
tance involve reactivation of the MAPK pathway 
due to events that can occur upstream, down-
stream, or at the level of BRAF; the PI3K-PTEN-
AKT pathway constitutes a second core resis-
tance pathway, which often overlaps with the 
MAPK pathway [26]. Interestingly, in progress-
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Figure 5. Effect of GR overexpression (GR-OX) or knockdown (GR-KD) on the 
tumor growth of iA2058- or iCOLO-679-bearing mice. Metastatic growth is 
shown in (A) and (B). Results obtained in these cells transfected with lenti-
viral vector not harboring any gene (GR-KD experiments) or empty plasmids 
(GR-OX experiments) (negative controls) were not different from control val-
ues. (C) Analysis of GR-OX and GR-KD were performed by measuring the GR 
content in melanoma cells. (D) GR-KD was also tested by western blot (a 
representative image is shown). Data are mean values ± SD from five to six 
different experiments (*P < 0.05, **P < 0.01, comparing RU486 treatment, 
GR-OX and GR-KD vs. controls).
Figure 6. Effect of dexamethasone (DXM) and VMF administration on the tu-
mor growth of (A) iA2058- or (B) iCOLO-679-bearing mice. VMF was adminis-
tered for 3 weeks starting on day 7 
after intradermic inoculation [VMF 
(7)] (as in Figure 2). DXM (0.2 mg/
kg per day) was administered for 2 
weeks starting on day 14 after in-
oculation. Data are mean values ± 
SD from 4-5 different experiments 
(*P < 0.05 comparing DXM and/
or VMF treatment vs. controls). (C) 
Plasma levels of corticosterone 
(COR) in control non-tumor-bear-
ing mice and in iA2058-bearing 
mice after DXM administration. 
Plasma levels of DXM were mea-
sured in iA2058-bearing mice af-
ter DXM administration. In these 
experiments DXM (0.2 mg/kg) 
was administered IV (one single 
dose) at 6 a.m. Blood was col-
lected from the tail vein during 
the 24-h period. Measurement of 
corticosterone and DXM was per-
formed as explained under Meth-
ods. Data are mean values ± SD 
from 6-7 different animals (*P < 
0.05, **P < 0.01, comparing COR 
levels in tumor-bearing mice vs. 
controls).
ing melanoma patient-derived 
xenografts, tumor growth in- 
hibition was observed when 
VMF was simultaneously ad- 
ministered with PD-0325901, 
a specific MEK inhibitor [27]. 
Nevertheless acquired resis-
tance to MAPK pathway tar-
geted therapies (BRAF/MEK 
inhibitors) develops in the ma- 
jority of patients at approxi-
mately 12 months [28]. It has 
been also reported that the 
MEK/ERK signaling pathway 
regulates the expression of di- 
fferent Bcl-2-related proteins 
and promotes survival of e.g. 
human pancreatic cancer cells 
[29]. 
RU486 decreases the antioxi-
dant defenses of melanoma 
cells and, thereby, increases 
ROS levels (Table 1). Higher 
ROS levels will favor metastat-
ic cell damage and death (not 
protection against apoptosis). 
As shown above, histopatho-
logical studies revealed that 
RU486 administration causes 
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a decrease in melanoma cell proliferation (Ki-
67 staining) and an increase in apoptotic cell 
death (TUNEL) (Figure 2). However, paradoxi-
cally, surviving cells upregulate anti-death 
mechanisms (Figure 3). Therefore, it is possible 
that specific/pro-survival adaptations in the 
Bcl-2 family of proteins could be involved in the 
resistance showed by the growing metastatic 
melanoma cells (Figure 3). We found that mice 
bearing metastatic BRAFV600E-mutated melano-
ma cells and treated with RU486, as compared 
to untreated controls, down regulate expres-
sion of different Bcl-2-related pro-death genes 
(i.e. bax, bak, bid); whereas upregulate anti-
death bcl-xl and mcl-1 (Figure 7A). Changes in 
gene expression equal or higher than 2-fold 
were further analyzed by western blotting 
(Figure 7B). Thus confirming that metastatic 
BRAFV600E-mutated melanoma cells surviving 
the treatment with the antagonist of GR upreg-
ulate a specific Bcl-2-related anti-death de- 
fense. 
Targeting of GR and Bcl-xL/Mcl-1 facilitates 
elimination of advanced BRAFV600E-mutated 
melanoma metastases by vemurafenib
Our next step was to test if pharmacological 
inhibition of Bcl-xL or Mcl-1 could improve the 
results of the combined administration of 
RU486 and VMF in advanced melanoma. We 
used WEHI-539 (a recently developed Bcl-xL-
selective BH3 mimetic) [30], and UMI-77 (a 
novel and selective small-molecule inhibitor of 
Mcl-1) [31]. RU486 was administered for 3 
weeks starting one week after inoculation of 
the metastatic cells (early growing period), 
whereas VMF, WEHI-539 and/or UMI-77 were 
administered for two weeks starting two weeks 
after inoculation of the metastatic cells (advan- 
ced growing period). 
Based on the results in Figure 7, it seems logic 
to think that Bcl-xl and Mcl-1 are main contribu-
tors of BRAF resistance. However, as shown in 
Table 2, the combined treatment of VMF and 
WEHI-539 and/or UMI-77 was not superior 
to VMF+RU486. Besides, the treatment with 
RU486+VMF+UMI-77 induced almost a com-
plete regression of advanced BRAFV600E-mu- 
tated iA2058 melanoma metastases (which 
overexpress mcl-1 by approx. 3.2 fold and bcl-
xL by approx. 2.0 fold as compared to mice 
treated only with RU486). In addition, the com-
bined treatment with RU486+VMF+WEHI-77+ 
UMI-77 was necessary to achieve metastas- 
es regression in mice bearing advanced BR- 
AFV600E-mutated iCOLO-679 melanoma metas-
Figure 7. Effect of RU486 treatment on the expression (A) and levels (B) of Bcl-2 family proteins in metastatic 
BRAFV600E-mutated melanoma cells isolated from in vivo growing tumors. iA2058 and iCOLO-679 cells were iso-
lated 2 weeks after intradermic inoculation (see under Experimental procedures). The data, expressing fold change 
(quantitative RT-PCR) (A), show mean values ± SD for 5-6 different experiments (*P < 0.05, **P < 0.01 for all genes 
displayed comparing cells isolated from RU486-treated mice (as in Figure 1) vs. controls. Protein levels (western 
blots) (B) for selected anti-death Bcl-2-related proteins were measured in metastatic cells 14 days after inoculation 
(n = 4-5, **P < 0.01, comparing cells isolated from RU486-treated mice vs. controls).
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Days after inoculation… 14 28 14 28
None 97 ± 36 421 ± 86 127 ± 35 955 ± 196
RU486 53 ± 17 147 ± 39** 84 ± 21 388 ± 117**
VMF (14) 85 ± 24 485 ± 116 116 ± 45 1061 ± 249
WEHI-539 74 ± 31 377 ± 112 133 ± 51 677 ± 155
UMI-77 66 ± 16 302 ± 94 149 ± 43 514 ± 147*
RU486 (14)+VMF (14) 57 ± 14 198 ± 57** 72 ± 18* 427 ± 101**
VMF (14)+WEHI-539 67 ± 25 355 ± 89 145 ± 61 615 ± 136
VMF (14)+UMI-77 55 ± 12 266 ± 75* 132 ± 74 474 ± 122*
WEHI-539+UMI-77 56 ± 26 240 ± 79** 102 ± 35 467 ± 106**
RU486+VMF (14)+WEHI-539 43 ± 15 155 ± 46** 96 ± 24 196 ± 63**
RU486+VMF (14)+UMI-77 51 ± 12 < 20** 65 ± 13** 155 ± 50**
VMF (14)+WEHI-539+UMI-77 51 ± 18 217 ± 83** 122 ± 50 403 ± 144**
RU486+VMF (14)+WEHI-539+UMI-77 62 ± 19 < 20** 77 ± 20* < 20**
RU486 was administered as in Figure 3. VMF was administered as in Figure 3 but starting 14 days after intradermic inoculation 
of the cancer cells. WEHI-539 (5 mg/kg IP, QD) (MCE, Monmouth Junction, NJ) and/or UMI-77 (50 mg/kg IV, QD) (Selleckchem, 
Houston, TX) wer e administered for 2 weeks also starting 14 days after inoculation of the cancer cells. WEHI-539 was dissolved 
in 10% DMSO, 40% PEG400, and 50% D5W. UMI-77 was dissolved in 10% DMSO, 70% Cremophor ELP, and 20% D5W. The 
volume administered to mice was, in both cases (WEHI-539 or UMI-77), < 50 mL. All data are mean values ± SD of 6-7 different 
animals in all groups (*P < 0.05; **P < 0.01 comparing all groups vs. controls).
Figure 8. Downregulation of Bcl-xL and Mcl-1 by specific inhibitors. WEHI-539 and UMI-77 administration and west-
ern blots were performed as in Table 2 (n = 4-5, **P < 0.01, comparing cells isolated from WEHI-539- or UMI-
77-treated mice vs. controls).
tases (which overexpress mcl-1 by approx. 4.2 
fold and bcl-xL by approx. 3.5 fold as compared 
to mice treated only with RU486, Figure 7A; 
Table 2). WEHI-539-induced Bcl-xL downregu-
lation and UMI-77-induced Mcl-1 downregula-
tion were confirmed by western blot (see Figure 
8). These results were validated using specific 
anti-bcl-xl-shRNA and anti-mcl-1-shRNA instead 
of the pharmacological inhibitors. As shown in 
Table 3, in mice bearing iA2058-mcl-1-shRNA 
melanoma cells treatment with RU486 and 
VMF causes a drastic decrease in metastases 
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Table 3. Effect of shRNA-induced selective Bcl-xL or Mcl-1 depletion 
on the efficacy of RU486 and vemurafenib against BRAFV600E-mutat-
ed metastatic melanoma
Melanoma cell variants Metastases volume (mm3)
Treatment None RU486+VMF (14)
iA2058 541 ± 151 257 ± 85#
iA2058-bcl-xl-shRNA 455 ± 120 179 ± 56#
iA2058-mcl-1-shRNA 449 ± 69 < 20*,#
iCOLO-679 833 ± 177 366 ± 91#
iCOLO-679-bcl-xl-shRNA 750 ± 155 156 ± 40*,#
iCOLO-679-mcl-1-shRNA 615 ± 103 130 ± 37*,#
iCOLO-679-bcl-xl-shRNA-mcl-1-shRNA 412 ± 112* < 20*
RU486 was administered as in Figure 3. VMF was administered as in Figure 3 but 
starting 14 days after intradermic inoculation of the cancer cells. Only melanoma 
cells treated with the specific shRNAs (see under Materials and Methods) were 
used in these experiments. Results obtained using melanoma cells treated with 
scrambled RNA sequences were not significantly different from those displayed 
as non-treated controls. All results displayed in the table correspond in all cases 
to metastases growth 28 days after intradermic inoculation. All data are mean 
values ± SD of 5-6 different animals in all groups (*P < 0.05 comparing iA2058 or 
iCOLO-679 control cells vs. their corresponding shRNA variants; #P < 0.05 comparing 
RU486+VMF-treated cells vs. non-treated cells).




Days after inoculation 14 28 14 28
None 126 ± 44 612 ± 184 135 ± 37 884 ± 206
RU486 78 ± 31 159 ± 41* 103 ± 36 317 ± 69*
VMF (14) 107 ± 32 577 ± 126 90 ± 29 954 ± 174
TRAM 145 ± 47 484 ± 134 147 ± 60 667 ± 196
COB 150 ± 52 749 ± 188 166 ± 55 1030 ± 284
RU486+VMF (14) 60 ± 27* 136 ± 37* 85 ± 21 384 ± 101*
VMF (14)+TRAM 50 ± 34* 317 ± 94* 73 ± 17* 414 ± 107*
VMF (14)+COB 93 ± 25 502 ± 106 116 ± 29 824 ± 169
RU486+VMF (14)+TRAM 53 ± 18* 99 ± 29* 61 ± 22* 148 ± 33*
VMF was administered as in Figure 3 but starting 14 days after intradermic inocu-
lation of the metastatic cells. Trametinib (TRA, GSK1120212) (0.3 mg/kg) and 
cobimetinib (COB) (5 mg/kg) were administered orally, daily (in a single dose) for 
14 consecutive days, and also starting 14 days after intradermic inoculation of the 
metastatic cells. TRA (Selleckchem, Houston, TX) was reconstituted in 100 μL vehicle 
(methocel/polysorbate buffer). COB (Selleckchem) was dissolved in 75 μL of 0.5% 
hydroxypropyl methylcellulose and 0.2% Tween-80. All data are mean values ± SD of 
5-6 different animals in all groups (*P < 0.05 comparing all groups vs. controls).
growth. A similar result was obtained in mice 
bearing iCOLO-679-bcl-xl-shRNA-mcl-1-shRNA 
melanoma cells treated with RU486 and VMF 
(Table 3). Thus suggesting that upregulation of 
specific anti-death Bcl-2-related proteins, such 
as Bcl-xL and/or Mcl-1 in the melanomas stud-
ied, may be key in the resistance of advanced 
BRAFV600E-mutated metasta-
ses against RU486 and VMF. 
Despite the efficacy shown 
by the combination of RU- 
486+VMF+specific anti-Bcl- 
2 therapy, at present, the 
BRAF-targeted therapy for 
melanoma is overwhelmingly 
dominated by the simultane-
ous use of BRAF+MEK inhibi-
tors. Hence, we also tested 
in the efficacy of VMF and 
two different MEK1/2 inhibi-
tors (cobimetinib, COB; and 
trametinib, TRAM) [32]. Both 
inhibitors were administered 
14 days after inoculation of 
the metastatic cells (advan- 
ced growing period). There- 
fore, the conditions of ad- 
vanced BRAFV600E-mutated 
melanoma growth were as 
in Table 3. As shown in Table 
4, metastatic growth was 
not significantly affected (as 
compared to controls) if any 
of the MEK inhibitors were 
administered alone. Combin- 
ed administration of VMF 
and TRAM (not COB) signifi-
cantly decreased melanoma 
growth (Table 4). Recently it 
was observed that VMF-re- 
sistant BRAFV600E-mutated 
melanoma was also regres- 
sed by TRAM, but not COB, in 
a patient-derived orthotopic 
xenograft mouse model [33]. 
Combined administration of 
RU486+VMF+TRAM further 
decreased melanoma grow- 
th (Table 4), but was not as 
effective as the combinati- 
on of RU486+VMF+specific 
anti-Bcl-2 therapy (Table 2).
As shown in Figure 9, survival was not signifi-
cantly improved in metastatic melanoma-bear-
ing mice treated with RU486, VMF or Bcl-xl 
and/or Mcl-1 inhibitors alone. Combination of 
RU486 and UMI-77 in iA2058-bearing mice 
or of VMF and WEHI-539+UMI-77 in iCOLO-
679-bearing mice slightly improved survival 
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Figure 9. Effect of treatment-induced regression of metastatic melanoma 
growth on host survival. RU486 and VMF were administered, as in Figure 
3, after intradermic inoculation of the cancer cells. WEHI-539 and UMI-77 
were administered, as in Table 1, but from day 7 to day 28. Host surviv-
al was studied in the following treatment conditions: (-) physiological sa-
line, (-) RU486, (-) VMF, (- -) UMI-77, (-) RU486+VMF, (- -) RU-486+UMI-77, 
(- -) VMF+UMI-77, (- -) RU486+VMF+UMI-77, (- -) WEHI-539+UMI-77, 
(- -) RU486+WEHI-539+UMI-77, (- -) VMF+WEHI-539+UMI-77, (- -) RU-
486+VMF+WEHI-539+UMI-77. Data are means ± SD for 20 different mice 
in each experimental condition.
(Figure 9). However, treatment of melanoma-
bearing mice (7 days after tumor inoculation, 
early growing period) with RU486+VMF signifi-
cantly increased host survival (Figure 9). 
Whereas treatment of melanoma-bearing mice 
(14 days after inoculation, advanced growth) 
with RU486+VMF+Bcl-xl and/or Mcl-1 inhibi-
tors further increased host survival (Figure 9).
Evaluation of drug-induced systemic toxicity
To evaluate potential side effects of the treat-
ment regimens, standard hematology, clinical 
chemistry, and urinalysis were studied in non-
tumor-bearing mice and in iA2058- and iCOLO-
679-bearing mice, treated with vehicles or the 
combinations shown to induce melanoma 
growth inhibition. As shown in Table S2 (avail-
able on request from the corresponding author), 
tumor growth-related side effects included 
anemia, neutropenia, low NK cell count, and an 
increase of several tissue da- 
mage-related enzyme activi-
ties in plasma, including aspar-
tate aminotransferase, alanine 
aminotransferase, GGT, alka-
line phosphatase, and lactate 
dehydrogenase (all common in 
cancer patients). 
Rates of glucose utilization by 
isolated hepatocytes and of 
glutamine and glucose by iso-
lated CD2+ lymphocytes were 
significantly increased in con-
trol melanoma-bearing mice 
as compared to non-tumor-
bearing mice, although were 
found similar in control mela-
noma-bearing mice and in mel-
anoma-bearing mice receiving 
full treatments (Table S2, avail-
able on request from the cor-
responding author). Thus sug-
gesting that normal rates of 
utilization of main energy-sup-
plying substrates are not 
compromised. 
GSH levels in isolated hepato-
cytes or CD2+ lymphocytes 
from control and treated mela-
noma-bearing mice were sig-
nificantly decreased (Table S2, 
available on request from the 
corresponding author), although within levels 
expected in non-tumor-bearing mice subjected 
to 24 h fasting. This is a known tumor growth-
derived effect associated to the interorgan 
GSH transport previously described in melano-
ma-bearing mice [34]. The cell volume of iso-
lated hepatocytes or lymphocytes remained 
similar in cells isolated from non-tumor or 
tumor-bearing mice (Table S2, available on 
request from the corresponding author). All 
suggesting that these normal cells appear to 
preserve their physiological status. Moreover, 
when isolated hepatocytes from treated tumor-
bearing mice and control non-tumor-bearing 
mice were cultured, their rates of growth were 
also similar.
These results clearly indicate that the toxicity 
caused by the treatments inducing metastatic 
melanoma growth inhibition, as compared to 
that associated to the tumor growth per se, 
appears clinically acceptable.
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Table 5. Effect of shRNA-induced selective AKT1 or NF-κB/p65 
depletion on the efficacy of vemurafenib and RU486 against 
BRAFV600E-mutated metastatic melanoma
Melanoma cell variants Metastases volume (mm3)
Treatment None VMF RU486+VMF
iA2058 502 ± 107 542 ± 125 254 ± 66#
iA2058-AKT1-shRNA 401 ± 88- 236 ± 69*,# 84 ± 26*,#
iA2058-NF-κB/p65-shRNA 456 ± 112 279 ± 77*,# 33 ± 12*,#
iCOLO-679 867 ± 206 984 ± 236 375 ± 119#
iCOLO-679-AKT1-shRNA 755 ± 177 721 ± 159 55 ± 17*,#
iCOLO-679-NF-κB/p65-shRNA 708 ± 146 769 ± 186 91 ± 24*,#
VMF was administered as in Figure 3 but starting 14 days after intradermic inocula-
tion of the cancer cells. RU486 was administered as in Figure 3. Results obtained 
using melanoma cells treated with scrambled RNA sequences were not significantly 
different from those displayed as non-treated controls. All results displayed in the 
table correspond in all cases to metastases growth 28 days after intradermic in-
oculation. All data are mean values ± SD of 6-7 different animals in all groups (*P < 
0.05 comparing iA2058 or iCOLO-679 control cells vs. their corresponding shRNA 
variants; #P < 0.05 comparing VMF- or VMF+RU486-treated cells vs. non-treated 
cells).
Figure 10. Effect of RU486 and VMF treatment on different Mcl-xL- and Mcl-
1-related signaling pathways in growing metastatic melanoma cells. Melano-
ma-bearing mice were treated with RU486 and VMF as in Figure 3, but VMF 
was administered starting 2 weeks after tumor inoculation. Representative 
western blot of different signaling-related factors. *P < 0.05, **P < 0.01 
comparing RU486- and/or VMF-treated mice vs. controls (mean values ± 
SD were calculated by densitometric analysis of n = 5-6 experiments, not 
shown).
Signaling pathways for modu-
lation of Bcl-xL and Mcl-1 in 
advanced BRAFV600E-mutated 
melanoma metastases
Upregulation of Bcl-xL and 
Mcl-1 expression in advanced 
BRAFV600E-mutated melanoma 
metastases treated with RU- 
486 may overcome the BRAF/
MEK/ERK signaling pathway. 
Thus resulting in resistance 
to VMF (Figure 3). In order to 
explore the underlying mecha-
nism, we investigated poten-
tial alternatives, i.e. PI3K-PT- 
EN-AKT- [26] and NF-κB-de- 
pendent signaling [35, 36]. As 
shown in Figure 10, treatment 
with RU486 results in an in- 
crease in Bcl-xL and Mcl-1 lev-
els in metastatic BRAFV600E-
mutated melanoma cells iso-
lated from in vivo growing tu- 
mors. This associates with a 
parallel increase in AKT, P-AKT 
and NF-κB binding to DNA, 
and a parallel decrease of 
IkBα and P-IkBα (Figures 10 
and S3, available on request 
from the corresponding au- 
thor). Treatment with RU486 
and VMF also causes a decre- 
ase in MEK1/2, P-MEK1/2, 
ERK1/2, and P-ERK1/2 with-
out affecting the RU486-in- 
duced increase in AKT- and 
NF-κB-dependent signaling (Fi- 
gure 10). Since the inhibitors 
of pan-PI3K signaling syner-
gize with BRAF or MEK inhibi-
tors to prevent BRAF-mutant 
melanoma cell growth [37], 
and the NF-κB pathway is acti-
vated in melanoma [22], our 
results suggest that PI3K-
PTEN-AKT- and NF-κB-depen- 
dent signaling mechanisms 
may be responsible of the re- 
sistance-related adaptations 
involving Bcl-xL and Mcl-1 in 
advanced BRAFV600E-mutated 
melanoma metastases. To va- 
lidate this hypothesis we used 
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specific anti-AKT1-shRNA and anti-NF-κB/
p65-shRNA. As shown in Table 5, melanoma 
resistance (associated to overexpression of 
Bcl-xL and Mcl-1) is decreased if AKT and NF- 
κB signaling pathways are blocked.
Discussion
GC, at the pathophysiological levels measur- 
ed in plasma of tumor-bearing models, show 
tumor-promoting activities [7]. We have shown 
that GR knockdown decreases the expression 
of GCL and GSH, SOD1 and SOD2, CAT, GPX, 
and GSR in highly metastatic B16-F10 melano-
ma cells. Thus compromising their antioxidant 
protection and, thereby, causing a drastic 
decrease in their survival upon interaction with 
endothelial cells in vitro and in vivo [8]. Here we 
show that administration of a GR antagonist 
(RU486) to mice bearing metastatic BRAFV600E-
mutated melanoma cells also decreases the 
antioxidant protection (Table 1; Figure 1) and 
growth of melanoma cells (Figure 1). The RU- 
486-induced inhibition of melanoma growth 
could be reversed by experimentally inducing 
Nrf2 overexpression (Figure 1). Thus illustrat-
ing the importance of the Nrf2-mediated anti-
oxidant defense system.
Production of large amounts of H2O2 by aggres-
sive human tumor cells was first reported by 
Szatrowski and Nathan [38]. It is now well 
established that cancer promotion and pro-
gression is linked to oxidative stress, which 
causes DNA damage and mutations, genome 
instability, and abnormal cell proliferation [39]. 
Elevated ROS levels appear balanced by an 
increased antioxidant capacity (where Nrf2 
plays a key role) within the cancer cells [40]. 
However an emerging concept postulates Nrf2 
as a double-edged sword: Nrf2 is required for 
the protection of the body against cancer by 
endogenous and pharmacological anticancer 
agents; but at the same time, it is overactivated 
in different tumors, thus resulting in a prosur-
vival phenotype that favors tumor growth and 
resistance to oxidants and oncotherapy [41, 
42]. DeNicola et al. [23] showed that Nrf2 defi-
ciency impairs the development of KRAS- and 
BRAF-driven tumors. Moreover, it has been 
demonstrated that early-stage cancer cells la- 
cking Nrf2 generate high ROS levels and ex- 
hibit a senescence-like growth arrest [23]. Mo- 
reover, besides oxidative stress-related genes, 
Nrf2 also controls expression of different heat-
shock proteins, drug-efflux pumps and growth 
factors (all promoters of cancer resistance 
and/or growth) [43]. 
The tumor suppressor p53 (reduced, lost, or 
mutated in approx. half of all human cancers, 
particularly in highly aggressive and metastatic 
cancers) is activated by DNA damage and regu-
lates the expression of many target genes lead-
ing to cell cycle arrest (thus allowing time for 
the repair of DNA damage) [44]. p53 can also 
interfere with the Nrf2-dependent transcription 
of ARE-containing promoters [45], and conse-
quently loss of p53 associates with increased 
ROS levels [46]. We demonstrated, in metastat-
ic B16 melanoma cells, that AS101 (an immu-
nomodulator that increases expression of wild-
type p53) caused a decrease in the expression 
of antioxidant enzymes [8]. Thus illustrating a 
cross-talk between p53 and Nrf2, and suggest-
ing that p53 might be exploited by melanoma 
cells to gain protection against oxidative st- 
ress. Interestingly GR activation may inhibit 
p53-induced apoptosis, as it occurs in MCF- 
10Amyc cells via induction of protein kinase Cε 
[47]. Whereas in estrogen receptor-positive 
breast cancer low GR expression has been 
associated with higher p53 expression [48]. 
In fact wild-type p53 can physically interact 
with the GR forming a complex that results in 
cytoplasmic sequestration of both p53 and GR 
[49]. Therefore, a molecular link among GR, 
p53 and Nrf2 may be key in the underlying 
mechanism supporting growth and dissemina-
tion of BRAFV600E-mutated melanoma cells.
VMF is used to treat adults with BRAFV600E-
mutated metastatic melanoma that cannot be 
surgically removed. It has been proven that 
VMF is effective at prolonging patients’ lives 
and delaying the worsening of the disease. The 
main study showed that patients taking VMF 
lived on average for 13.2 months compared 
with 9.9 months for patients on dacarbazine, 
and it took on average 5.3 months for the dis-
ease to worsen in the VMF group compared 
with 1.6 months in the dacarbazine group (see 
e.g. [50]). Corazao-Rozas et al. reported that 
VMF increased mitochondrial respiration and 
ROS production in BRAFV600E-mutated melano-
ma cell lines, and that melanoma cells showing 
acquired resistance to VMF displayed intrinsi-
cally high rates of mitochondrial respiration 
associated with elevated mitochondrial oxida-
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tive stress [10]. Therefore, targeting of melano-
ma antioxidant defense could represent an 
effective strategy. As shown in Figure 3, com-
bined administration of RU486 and VMF pro-
motes regression of early melanoma metasta-
ses. However, a delay in VMF administration 
represented a loss of therapeutic efficacy 
(Figure 3). Thus suggesting additional adaptive 
mechanisms favoring melanoma cell survival, 
which were identified as Bcl-2 protein family-
related mechanisms (Bcl-xL and Mcl-1 in the 
melanoma models used) [Figures 7, 10; Table 
S2 (available on request from the correspond-
ing author) and Table 3]. At present successful 
initial clinical trials of the BH3 mimetic veneto-
clax/ABT-199, specific for Bcl-2, have led to its 
recent licensing for refractory chronic lympho-
cytic leukemia and to multiple ongoing trials for 
other malignancies [51]. Moreover, preclinical 
studies herald the potential of emerging BH3 
mimetics targeting other Bcl-2 pro-survival 
members, particularly Mcl-1, for multiple can-
cer types [51]. Thus suggesting that our find-
ings may have clinical applications.
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Table S1. Genetic background of the mela-




BRAF V600E V600E V600E
NRAS (exon 3) WT WT WT
TP53 V274F WT 145L/R
PTEN +/- +/- +/-
CDKN2A WT WT WT
CDK4 WT WT R24C
BRAF and CDK4 mutational status were determined by 
direct sequencing of PCR- amplified genomic fragments 
of exons 15 and 2, respectively. p53 mutational status 
was determined by direct sequencing of exons 2-10 by 
RT-PCR. PTEN levels were determined by immunoblotting 
and normalized to control melanocytes (+/- indicates no 
variation compared with human melanocytes). WT, wild 
type.
Figure S1. Effect of RU486 treatment on lipid peroxidation in metastatic human melanoma cells. 8-Isoprostane 
levels were measured to evaluate lipid peroxidation as indicated under Experimental procedures. Data are mean 
values ± SD of five to six different animals. **P < 0.01, comparing RU486-treated mice vs. controls (as in Table 1). 
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Table S2. Hematology, clinical chemistry, and urinary balance data in metastatic human melanoma-






Control RU486+VMF +UMi-77 Control
RU486+VMF++ 
WEHi-539+UMi-77
Hematology      
    Hematocrit (%) 38.7 ± 1.8 33.5 ± 2.5 30.2 ±1.6** 30 ± 1.7** 27 ± 1.2**
    Hemoglobin (g/dL) 12.3 ± 0.3 12.0 ± 0.5 11.2 ± 0.4* 11.2 ± 0.5* 10.2 ± 0.2**,#
    Erythrocytes (106/mL) 8.5 ± 0.3 7.0 ± 0.1** 6.5 ± 0.2**,# 6.7 ± 0.2** 6.3 ± 0.1**
    Platelets (103/mL) 412 ± 46 365 ± 70 260 ± 41** 333 ± 36* 170 ± 25**,##
    Leukocytes (103/mL) 2.6 ± 0.3 2.5 ± 0.2 2.0 ± 0.2*# 2.4 ± 0.4 1.7 ± 0.1**,##
    Lymphocytes (103/mL) 1.2 ± 0.3 1.3 ± 0.2 1.0 ± 0.1 1.2 ± 0.2 0.9 ± 0.15
    % CD3 1.5 ± 0.1 1.2 ± 0.2 1.3 ± 0.1 1.1 ± 0.15* 1.1 ± 0.2*
    % CD4 0.9 ± 0.1 1.0 ± 0.2 1.0 ± 0.2 0.7 ± 0.1* 0.8 ± 0.1
    % CD8 0.3 ± 0.05 0.4 ± 0.1 0.3 ± 0.05 0.5 ± 0.2 0.3 ± 0.1
   % B Cells 55.4 ± 7.8 47.7 ± 8.6 52.4 ± 5.4 42.4 ± 7.7 40.1 ± 6.3*
    % NK 7.5 ± 1.2 3.8 ± 1.0** 4.2 ± 0.6** 4.1 ± 1.3** 5.0 ± 0.9**
    Neutrophils (103/mL) 1.1 ± 0.2 0.5 ± 0.1** 0.5 ± 0.1** 0.4 ± 0.05** 0.5 ± 0.1**
    Monocytes (103/mL) 0.1 ± 0.05 0.1 ± 0.05 0.1 ± 0.05 0.05 ± 0.02 0.15 ± 0.03
    Eosinophils (103/mL) 0.05 ± 0.01 0.1 ± 0.02 0.05 ± 0.02 0.1 ± 0.05 0.05 ± 0.01
    Basophils (103/mL) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
    Plasma osmolarity (mOsm/kg) 296 ± 17 275 ± 11 312 ± 13## 345 ± 20 317 ± 14
Clinical chemistry      
    Urea (mg/dL) 45.7 ± 5.1 55.6 ± 6.4 54.7 ± 5.7 59.3 ± 4.9** 56.4 ± 5.6*
    Uric acid (mg/dL) 1.7 ± 0.2 1.9 ± 0.3 1.5 ± 0.3 2.2 ± 0.4* 1.7 ± 0.3
    Total protein (g/dL) 4.2 ± 0.2 3.5 ± 0.1** 3.3 ± 0.4** 3.2 ± 0.5** 3.1 ± 0.2**
Figure S2. Effect of Nrf2 overexpression on the expression of different Nrf2-dependent genes in isolated iA2058 
and iCOLO-679 cells from RU486-treated tumor-bearing mice. Tumor-bearing mice were treated with vehicle (con-
trols) or RU486 as in Table 1. All data, expressing fold change (quantitative RT-PCR, see under Experimental proce-
dures for calculations), show mean values ± SD for five to six different experiments. *P < 0.05, **P < 0.01 compar-
ing RU486-treated tumor-bearing mice vs. control tumor-bearing mice treated with physiological saline.
Glucocorticoid receptor antagonism in metastatic melanoma
3 
    Albumin (g/dL) 3.0 ± 0.3 2.7 ± 0.4 2.5 ± 0.2 2.4 ± 0.5 2.5 ± 0.2
    Creatinine (mg/dL) 0.4 ± 0.1 0.5 ± 0.1 0.6 ± 0.2 0.6 ± 0.1 0.5 ± 0.1
    Glucose (mg/dL) 136 ± 15 174 ± 16* 155 ± 14 179 ± 20* 134 ± 17#
    Total bilirubin (mg/dL) 0.5 ± 0.1 0.4 ± 0.05 0.4 ± 0.1 0.5 ± 0.2 0.4 ± 0.1
    Direct bilirubin (mg/dL) 0.1 ± 0.01 0.05 ± 0.02 0.1 ± 0.01 0.1 ± 0.01 0.1 ± 0.01
    Aspartate aminotransferase (IU/L) 125 ± 36 256 ± 21** 316 ± 46** 274 ± 29** 340 ± 38**
    Alanine aminotransferase (IU/L) 7.7 ± 1.6 38.9 ± 9.7** 45.6 ± 17.4** 44.0 ± 12.9** 49.4 ± 15.6**
    GGT (IU/L) 1.9 ± 0.3 4.2 ± 0.5** 4.1 ± 0.2** 3.7 ± 1.0** 4.6 ± 0.7**
    Alkaline phosphatase (IU/L) 106 ± 21 144 ± 24 166 ± 17** 161 ± 29** 184 ± 30**
    Lactate dehydrogenase (IU/L) 176 ± 37 425 ± 59** 517 ± 66** 460 ± 58** 477 ± 74**
    Sodium (mEq/L) 155 ± 15 136 ± 24 115 ± 16 124 ± 23 130 ± 19
    Potassium (mEq/L) 8.9 ± 1.3 9.2 ± 1.5 10.4 ± 1.1 10.7 ± 1.7 8.5 ± 2.0
    Chloride (mEq/L) 91 ± 12 70 ± 14 62 ± 11* 78 ± 9 84 ± 16
Isolated hepatocytes      
    GSH (nmol/g of cells) 6243 ± 326 3504 ± 244** 3009 ± 491** 3017 ± 204** 2508 ± 317**
    Cell volume (mL/mg dry wt.) 3.1 ± 0.3 3.2 ± 0.2 3.0 ± 0.4 3.0 ± 0.1 2.9 ± 0.3
    Glucose utilization (mmol/g x min) 1.55 ± 0.33 2.14 ± 0.15** 1.66 ± 0.21## 2.49 ± 0.22** 1.59 ± 0.16##
Isolated CD2+lymphocytes      
    GSH (nmol/106 cells) 5.6 ± 1.1 2.7 ± 0.6** 2.2 ± 0.9** 2.5 ± 0.5** 2.0 ± 0.4**
    Cell volume (mm3) 161 ± 24 145 ± 17 147 ± 21 155 ± 26 150 ± 18
    Glucose utilization (mmol/g x min) 1.76 ± 0.20 2.40 ± 0.15** 1.84 ± 0.17## 2.80 ± 0.23** 2.04 ± 0.22##
    Glutamine util. (mmol/g x min) 3.40 ± 0.17 4.50 ± 0.49** 4.05 ± 0.42* 4.06 ± 0.33** 3.81 ± 0.55
Urinary balance      
    pH 7.5 ± 0.3 7.8 ± 0.4 8.2 ± 0.3* 7.7 ± 0.5 7.8 ± 0.2
    Leukocytes (mL-1) Negative Negative Negative Negative Negative
    Erythrocytes (mL-1) Negative Negative Negative Negative Negative
    Nitrite Negative Negative Negative Negative Negative
    Protein (g/L) 0.2 0.2 0.4 0.2 0.2
    Glucose Normal Normal Normal Normal Normal
    Ketones Negative Negative Negative Negative Negative
    Urobilinogen Normal Normal Normal Normal Normal
    Bilirubin Negative Negative Negative Negative Negative
    GFR (mL/min) 188 ± 36 171 ± 25 177 ± 27 164 ± 33 169 ± 18
Full treatment means the combination of RU486+VMF+UMI-77 in iA2058-bearing mice and of RU486+VMF+WEHI-539+UMI-77 in iCOLO-
679-bearing mice. Standard cell count and chemistry were measured in peripheral blood samples taken from the saphena vein. Data are means ± 
SD for 7-8 different mice in each experimental condition. *P < 0.05 and **P < 0.01 comparing tumor-bearing mice vs. non-tumor-bearing mice. #P 
< 0.05 and ##P < 0.01 comparing, under tumor-bearing mice, full treatment vs. treatment with vehicles.
Figure S3. Effect of RU486 and VMF treatment on different Mcl-xL- and Mcl-1-related signaling pathways in growing 
metastatic melanoma cells. Melanoma-bearing mice were treated with RU486 and VMF as in Figure 3, but VMF was 
administered starting 2 weeks after tumor inoculation. NF-κB binding to DNA (data are mean values ± SD of 4-5 
different animals in all groups; **P < 0.01 comparing RU486- and/or VMF-treated mice vs. controls).
